Gerresheimer expecting 4% to 6% revenue growth in medium term

Duesseldorf/Buende (ots) -

- Cross reference: The full press release including tables is
available at: http://www.presseportal.de/dokumente -

- Gerresheimer sees good growth opportunities in long-term
megatrends of pharma and healthcare
- Growing importance of drug delivery and dosage devices in
Western markets and of pharmaceutical primary packaging business
in emerging markets
- Mid-term growth potential 2016 to 2018: 4% to 6% average organic
revenue growth and up to 21% adjusted EBITDA margin
- Initial indications for financial year 2015: around 1% to 3%
organic revenue growth and up to EUR 10m higher adjusted EBITDA

Gerresheimer AG set out its strategy at a Capital Markets Day held
in Buende, Westphalia. "Health and well-being are issues taking on
ever greater global significance. I believe we have very strong
medium-term growth prospects with our products becoming increasingly
important. We are outstandingly well placed with our broad product
portfolio, experience and proximity to the customer. We aim to grow
in promising pharma markets, develop innovative products for safe and
simple drug delivery and expand local production in the main emerging
economies," explained Uwe Röhrhoff, CEO of Gerresheimer AG, speaking
to investors and analysts. "We will invest heavily in production
capacity as well as in standardizing our technologies and in quality
systems. This is the basis for healthy medium-term growth for our
Company."

CEO Röhrhoff took investors and analysts through key trends in the
growing pharma markets and charted Gerresheimer's plans for
successful growth based on those trends. "The pharma and healthcare
markets offer attractive prospects and are growing continually. Our
strategy for profitable growth is in place and we are successful both
with our high-quality glass and plastic pharmaceutical primary
packaging and with complex products like insulin pens, inhalers,
autoinjectors and prefillable syringes. I am very optimistic for the
future of our Company," Röhrhoff said.

Medium-term outlook and initial indications for 2015

Gerresheimer reaffirmed its medium-term guidance for revenue
growth at the Capital Markets Day. For the years 2016 to 2018, the
Company expects average annual organic revenue growth of some 4% to
6% at constant exchange rates. Alongside this, the Company held out
the prospect of an adjusted EBITDA margin of up to 21% in the same
period. Capital expenditure is expected to be around 9% to 10% of
revenues.

Gerresheimer also gave initial indications for financial year
2015, to be followed up with more precise figures in February 2015 on
presentation of the 2014 annual financial statements. The Company
plans to streamline its portfolio in 2015. It will continue
standardizing to trim costs. Further investment in capacity expansion
is also on the agenda for the US, India and the Czech Republic. On a
very preliminary estimate, Gerresheimer anticipates organic revenue
growth of around 1% to 3% at constant exchange rates in financial
year 2015. With regard to earnings, Gerresheimer expects adjusted
EBITDA to climb by up to EUR 10m in 2015. Capital expenditure is
expected to be around 9% to 10% of revenues at constant exchange
rates.

Key trends for tomorrow's pharma market

The Company eyes six key trends for the future of pharma markets:

- Patents on numerous drugs are expiring at the same time as
generic drugs gain ground.
- More people in emerging markets have access to healthcare and
hence to medication.
- Regulatory requirements relating to drugs are increasing
globally. This is already evident today in stricter regulation
by US health authorities.
- New drugs are emerging, many of them biotech-based, with special
requirements in terms of administration and packaging.
- Chronic diseases such as asthma and diabetes are on the increase
worldwide.
- There is a growing trend toward self-medication by patients.

Success strategy for the Plastics & Devices Division

Based on the key healthcare market trends, Gerresheimer is forging
ahead with its strategy for its two main divisions. In the Plastics &
Devices Division, Gerresheimer develops and produces complex,
customer-specific products for safe and simple drug delivery and
dosage, including pens, inhalers and prefillable glass syringes.
There is notable growth in demand for these products in Europe and
North America, where Gerresheimer holds a strong position (number one
or two) in each submarket it serves. The Company is adding to
production capacity and expanding global development centers for such
products. In prefillable syringes, the Company sets new standards of
quality and flexibility with its very latest, fourth production line
in its global Syringe Competence Center in Buende, Germany. Other
innovations in this sector relate to new materials, such as
sophisticated plastics like COP, suitable as an alternative for some
drug packaging products. The Company also gave a heads-up insight
into its project pipeline for medical plastic systems. In the plastic
drug packaging product category, Gerresheimer targets innovations in
closures, caps and dosage systems along with growth in South American
and Asian emerging economies, where it has several plants.

Success strategy for the Primary Packaging Glass Division

In its second major division, Gerresheimer produces glass primary
packaging items such as injection vials, ampoules, cartridges and
pharma bottles. Here, too, it holds strong, number one or number two
positions with a broad product range in the European, North American
and emerging markets. In light of increasing regulatory requirements
for drugs and drug packaging, Gerresheimer's strategy consists in
further improving quality as well as continuing to standardize
technologies and production processes across all plants worldwide. In
terms of upcoming investment to expand production, the priority is on
Asia and above all India. While glass is the oldest and still remains
unbeaten as the best material for safe, long-term packaging and
transportation of pharmaceuticals, this is nonetheless another area
where Gerresheimer continues to push the innovation envelope. As a
case in point, the Company is working on innovations in the
manufacture of glass used in pharmaceutical applications.

Producing sophisticated cosmetic glass is a good supplementary
business in this division. Key factors here include extended
capabilities in glass processing and decoration. Here, Gerresheimer
is outstandingly well placed for the future, notably in the European
cosmetics market, with a broad range of innovative products and
finishing technologies.

The full Capital Markets Day strategy presentation and the
recorded webcast are available online at
http://www.gerresheimer.com/en/investor-relations/

The third quarter 2014 press release is available here:
www.gerresheimer.com/nc/en/news-events/press-releases/corporate-news

The Interim Report is available at:
http://www.gerresheimer.com/en/investor-relations/reports

Pressekontakt:
Gerresheimer AG
Klaus-Bungert-Strasse 4
40468 Duesseldorf
Germany

Jens Kürten
Director Corporate Communication & Marketing
Phone +49 211 6181-250
Fax +49 211 6181-241
E-Mail j.kuerten@gerresheimer.com
Internet www.gerresheimer.com